RxDoctor Payments Data

Ryan McComb, MD

Family Medicine · Pahrump, NVNPI 1669813952

Payments from drug & device makers

$840in general payments, 2019–2025

Across 44 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$199
  • Lilly USA, LLC$170
  • AbbVie$64
  • Otsuka America Pharmaceutical, Inc.$63
  • Dexcom, Inc.$45
  • Merck$39
  • plus $261 from 11 others

What the payments were for

  • Food & beverage$840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$840 in reported general payments places this provider in the 65th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$65,979
Medicare patients
263
Services billed
1,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$49,397
OzempicSemaglutide35$49,302
XareltoRivaroxaban24$25,251
LinzessLinaclotide19$17,324
EntrestoSacubitril/Valsartan17$17,005
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,664
SymbicortBudesonide/Formoterol Fumarate16$4,222
Omeprazole150$2,800
Atorvastatin Calcium277$2,675
Albuterol Sulfate HfaAlbuterol Sulfate109$2,506
Gabapentin147$2,475
Levothyroxine Sodium230$2,150
Rosuvastatin Calcium154$1,700
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,592
Tamsulosin Hcl132$1,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$199$49,30235 claims
AbbVieLinzess$64$17,32419 claims
GSKTrelegy Ellipta$37$12,66414 claims
AstraZenecaSymbicort$33$4,22216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 902 family medicine providers in Nevada.

Other family medicine in Pahrump

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →